RXi hopes to market dermatology business after landing patent
Photo | Brad Kane
Geert Cauwenbergh, president and CEO, RXi Pharmaceuticals Corp., Marlborough.
Marlborough drugmaker RXi Pharmaceuticals has been granted a U.S. patent for its method to treat or prevent fibrotic disorders, and hopes to market that intellectual property as it continues to focus on cancer research.
The particular patent comes after a recent clinical trial displayed the safety and effectiveness of a substance, RXI-109, and its use to treat scarring of the skin brought from fibrotic disorders.
The announcement comes just months after the company announced in January its intention to focus exclusively on developing immuno-oncology treatments and partner or out-license its dermatology and ophthalmology businesses.
In the company’s Tuesday announcement on the patent, the company asks any interested parties to contact its director of business development, Gerrit Dispersyn.
In a statement, Dispersyn said the clinical data and strong intellectual property by way of the newly granted patent will be key to landing a potential partner.
The company began the year with a renewed focus on developing cancer treatments in the immuno-oncology realm via its self-delivering RNAi-based technology platform. The company has formed four partnerships with European institutions and companies to expand its pipeline in the cancer-solving industry.
RXi has populated its leadership positions with immuno-oncology experts, including positions on its scientific advisory board, board of directors and the position of chief development officer.
WBJ Web Partners
Most Recent
Most Recent
0 Comments